美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床疗效

目的：分析曲美他嗪联合美托洛尔对于冠心病心力衰竭的临床疗效。方法随机选择100例2013年12月—2015年12月于该院接受治疗的冠心病心力衰竭患者,随机将所有患者按照每组50例分为观察组与对照组。对照组：患者入院后行常规治疗,于此基础上给予琥珀酸美托洛尔缓释片初始剂量6.25 mg/d。观察组在对照组治疗方案基础上增加盐酸曲美他嗪片20 mg/d,餐前服用。观3个月后观察两组患者的临床疗效以及治疗前后患者各项等指标变化情况。结果两组患者接受不同的治疗方案后,发现观察组的显效率(42.0%)以及总有效率(98.0%)显著优于对照组的显效率(28.0%)以及总有效率(86.0%),两组比较差异具有统计学意义(P<0.05)。治疗前两组患者SBP、DBP、HR、LVEDD、LVESD、LVEF各项指标差异无统计学意义(P>0.05),经过3个月治疗后,患者各项指标与治疗前相比均有所改善,而且观察组改善的更为明显,与对照组相比较差异具有统计学意义(P<0.05)。治疗后观察组血浆BNP明显高于对照组,差异有统计学意义(P﹤0.05)。结论曲美他嗪联合美托洛尔对于冠心病心力衰竭具有很好的临床疗效。

QuMei Clinical Curative Effect of Metoprolol Combined with Trimetazidine Treatment of Coronary Heart Disease and Heart Failure

Objective Observation of QuMei trimetazidine combined with metoprolol for the clinical efficacy of coronary heart disease and heart failure. Methods Random selection 100 patients with coronary heart disease and heart failure who were treated in our hospital from December 2015 to December 2013 were selected, All patients were randomly divided into observation group and control group, 50 cases in each group were randomly divided into two groups. Patients in the control group were treated with routine treatment after admission, Based on this give Metoprolol Succinate Sustained-release Tablets the initial dose of 6.25 mg/d. The observation group added Trimetazidine Dihydrochloride Tablets 20 mg/d in the control group treatment program, before meals. After 3 months, the clinical efficacy of the two groups were observed and the changes of the patients before and after treatment were observed. Results Two groups of patients were treated with different treatment options, Significant efficiency(42.0%) and total effective rate(98.0%) of the observation group was significantly bet-ter than that of the control group (28.0%) and total effective rate (86.0%), The difference between the two groups was statis-tically significant (P<0.05). Before treatment, two groups of patients with SBP, DBP, HR, LVEDD, LVESD, LVEF indicators of no difference between groups (P>0.05), After 3 months of treatment, the indicators of patients were improved compared with before treatment, and the observation group improved more significantly, compared with the control group with statisti-cal difference (P<0.05). After treatment, the plasma levels of BNP in the observation group were significantly higher than those in the control group, the difference was statistically significant (P<0.05). Conclusion Sibutramine trimetazidine com-bined with metoprolol has good clinical efficacy for coronary heart disease and heart failure.